Opinion|Videos|February 27, 2026
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
Author(s)Joel Neal, MD, PhD, Sarah B. Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss the clinical role of amivantamab plus lazertinib in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, evaluate the clinical data supporting amivantamab plus lazertinib in EGFR-mutated NSCLC. Neal outlines the mechanistic rationale for dual EGFR and MET targeting and reviews efficacy outcomes from pivotal studies. Goldberg contextualizes this combination within current sequencing strategies and frontline decision-making.
Advertisement
Related to this article
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5